Red Maple LifeSciences

MISSION RELEVANCE

EnzyLock for Combat Casualty Care

EnzyLock is a bacteria-responsive smart hydrogel designed for infection-prone wounds. Its detection and triggered-treatment functions are well suited to austere and resource-limited care settings, including prolonged field care and far-forward medicine, where lab diagnostics and rapid evacuation may not be available.

This page describes translational and mission relevance. It does not claim field testing, military use, or battlefield validation.

THE PROBLEM

Infection Burden in Combat Trauma

  • Wound infections occur in 17-25% of combat-related injuries treated at US military treatment facilities. Of these infections, 14-22% are caused by multidrug-resistant bacteria.[1]
  • Roughly one-third of casualties evacuated to US hospitals from Iraq and Afghanistan developed an infection during initial hospitalization.[2]
  • In DoD-VA follow-up cohorts, 38% of enrolled patients developed a new trauma-related infection after initial hospital discharge, with skin and soft-tissue infections and osteomyelitis predominant.[3]

RESISTANCE

The Resistance Problem

  • Acinetobacter baumannii is one of the most common pathogens in combat-related skin and soft tissue injuries (approximately 35% of cases), and up to 90% of those isolates are multidrug-resistant.[1]
  • In a Walter Reed Army Medical Center study, 89% of 75 patient isolates were resistant to at least three antibiotic classes, and 15% were resistant to all nine antibiotics tested.[4]
  • Overuse of broad-spectrum empiric antibiotics, driven by delayed or unavailable culture diagnostics, is considered a significant driver of this resistance.[5]

WHY ENZYLOCK

An Approach That Fits This Gap

EnzyLock integrates two core functions already described on our Product page: real-time bacterial detection through visible color change, and precision antimicrobial delivery triggered only by bacterial presence.

  • Lab-free infection signal

    A bacteria-triggered colorimetric signal requires no lab, no reader, and no power. Clinicians can see infection without waiting 48-72 hours for culture results. That is directly relevant where prolonged field care and delayed evacuation make lab-based diagnostics unavailable.[6][5]

  • Infection-triggered release

    The platform enables localized, controlled release of encapsulated therapeutic cargo when infection is present, reducing unnecessary antibiotic exposure. That design supports antibiotic stewardship goals that matter given the resistance rates described above.

  • Platform breadth

    EnzyLock is engineered for infection-prone wounds across clinical settings. The same detection and triggered-delivery approach is relevant to trauma and post-surgical wound care in both deployed and garrison environments, without requiring a change in core wound care workflow.

Sources

Figures below are from the cited literature and public DoD-linked sources. They are not Red Maple LifeSciences data.

  1. [1] Rapid, label-free pathogen identification system for multidrug-resistant bacterial wound infection detection on military members in the battlefield. NCBI/PMC9070933.
  2. [2] Blast Injury Research Coordinating Office / DoD-VA Trauma Infectious Disease Outcomes Study (TIDOS). blastinjuryresearch.health.mil.
  3. [3] Trauma-related infection after hospital discharge in DoD-VA follow-up cohorts. PMC6160604.
  4. [4] Multidrug-resistant Acinetobacter isolates, Walter Reed Army Medical Center. Antimicrobial Agents and Chemotherapy. journals.asm.org/doi/10.1128/aac.00778-06.
  5. [5] Diagnostic Innovations to Combat Antibiotic Resistance in Critical Care. PMC12428289.
  6. [6] Prolonged field care as a top Army priority capability gap. PMC6893012.